Dasiglucagon低血糖“救援笔”快速有效治疗糖尿病患者的严重低血糖：3期试验结果
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
关键信息
- 胰高血糖素是用于糖尿病患者因胰岛素治疗而发生严重低血糖的急救药物。
- 胰高血糖素存在处方不足和使用不当的问题。过去的胰高血糖素注射剂使用有多个准备步骤，需要提前进行用户培训。 这些是其处方和有效利用的障碍，尤其在紧急情况下。
- Dasiglucagon是一种特定的胰高血糖素受体激动剂，用7个氨基酸取代天然胰高血糖素的部分结构，使其在水溶液中维持物理和化学性质的稳定。
- 这项研究表明，Dasiglucagon是一种快速有效的治疗严重低血糖的方法。自动注射器形式的和双激素闭环泵系统中使用的Dasiglucagon具有使糖尿病胰岛素治疗患者受益的潜力。
Presenting Author
Timothy S Bailey, MD, FACE
President & CEO, AMCR Institute (Escondido, CA)
Clinical Associate Professor, Department of Medicine, UC San Diego School of Medicine
Dr. Bailey is the CEO and President of the AMCR Institute in Escondido, California and a clinical associate professor of medicine at the University of California at San Diego, where he helps to train endocrinology fellows. He is a past president of the California chapter and former board member of the American Association of Clinical Endocrinologists.
He has served as Principal Investigator on more than 200 phase 1 to 4 clinical trials testing new medications and technology for diabetes including sensors, delivery devices, and the "artificial pancreas". He has a particular interest in human factors testing and real-world trials, with the goal of improving adherence, persistence and the overall effectiveness of therapies for people with diabetes.
Disclosures
Research Support: Abbott, Capillary Biomedical , Dexcom, Diasome, Eli Lilly, Kowa, Lexicon, Medtronic, Medtrum, Novo Nordisk, REMD, Sanofi, Senseonics, Viacyte, vTv Therapeutics, Zealand Pharma
Consulting Honoraria: Abbott, Lifescan, Novo, Sanofi
Speaking Honoraria: Medtronic, Sanofi
